BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Argus Health

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,107,302

« Back to Dashboard

Which drugs does patent 6,107,302 protect, and when does it expire?

Patent 6,107,302 protects VALTREX and is included in one NDA.

Protection for VALTREX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in forty countries.

Summary for Patent: 6,107,302

Title: Guanine derivative
Abstract:The invention relates to an anhydrous crystalline form of (2-[2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy]ethyl L-valinate hydrochloride (otherwise known as valaciclovir hydrochloride) and a process for preparing it.
Inventor(s): Carter; Barry Howard (Kinston, NC), Partin; Jane Muse (Raleigh, NC), Varlashkin; Peter Gregory (Clayton, NC), Winnike; Richard Augustus (Durham, NC), Grubb, III; William Bayne (Athens, GA), Conway; Gregory Alan (Greenville, SC), Lake; Philip George (Dartford, GB), Skinner; David Michael (Dartford, GB), Whatrup; David James (Dartford, GB)
Assignee: Glaxo Wellcome Inc. (Research Triangle Park, NC)
Application Number:08/875,173
Patent Claim Types:
see list of patent claims
Compound; Use; Process; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
GlaxosmithklineVALTREXvalacyclovir hydrochlorideTABLET;ORAL020487-002Jun 23, 1995ABRXYesYes► Subscribe► Subscribe► Subscribe
GlaxosmithklineVALTREXvalacyclovir hydrochlorideTABLET;ORAL020487-001Jun 23, 1995ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,107,302

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9501178Jan 20, 1995
PCT Information
PCT FiledJanuary 19, 1996PCT Application Number:PCT/GB96/00117
PCT Publication Date:July 25, 1996PCT Publication Number: WO96/22291

International Patent Family for Patent: 6,107,302

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Spain2248806► Subscribe
European Patent Office0804436► Subscribe
Estonia03528► Subscribe
Estonia9700175► Subscribe
Eurasian Patent Organization000364► Subscribe
Denmark0804436► Subscribe
Germany69635106► Subscribe
Czech Republic297065► Subscribe
Czech Republic9702294► Subscribe
Cyprus2531► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
Cantor Fitzgerald
Federal Trade Commission
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: